| scholarly article | Q13442814 |
| P50 | author | Shruti Chaturvedi | Q59679810 |
| Keith R McCrae | Q60839328 | ||
| P2093 | author name string | Keith R McCrae | |
| Shruti Chaturvedi | |||
| P2860 | cites work | Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines | Q22255576 |
| Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant | Q24247000 | ||
| Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) | Q24558202 | ||
| VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632982 | ||
| Meningococcal Vaccinations | Q26752993 | ||
| Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke | Q28167141 | ||
| A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) | Q28174751 | ||
| Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment | Q28193717 | ||
| Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator | Q28193764 | ||
| Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals | Q28210153 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab | Q28260452 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor | Q28565242 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| E-Selectin mediates pathogenic effects of antiphospholipid antibodies | Q33349081 | ||
| Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin | Q33363054 | ||
| beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation | Q33375186 | ||
| Prevention of murine antiphospholipid syndrome by BAFF blockade | Q33380975 | ||
| Use of rituximab in the antiphospholipid syndrome | Q33389337 | ||
| A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome | Q33404206 | ||
| Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis | Q33406588 | ||
| Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients | Q33412915 | ||
| Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. | Q33419171 | ||
| Current treatment of antiphospholipid syndrome: lights and shadows | Q33423959 | ||
| Activation of cultured vascular endothelial cells by antiphospholipid antibodies. | Q33488617 | ||
| The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. | Q33504222 | ||
| Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. | Q33576496 | ||
| Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome | Q33630007 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. | Q41818166 | ||
| Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice | Q41927420 | ||
| Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome | Q42674523 | ||
| Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome | Q42969030 | ||
| Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospholipid syndrome | Q43090289 | ||
| In vitro model of annexin A5 crystallization on natural phospholipid bilayers observed by atomic force microscopy | Q43265575 | ||
| Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants | Q43463817 | ||
| Recent guidelines and recommendations for laboratory detection of lupus anticoagulants | Q43594150 | ||
| Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. | Q43626449 | ||
| Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies | Q43719415 | ||
| Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype | Q43837381 | ||
| Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo | Q44106531 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| Comparison of different kits in the detection of autoantibodies to cardiolipin and beta2glycoprotein 1 | Q44636973 | ||
| Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients | Q44830352 | ||
| GAPSS: the Global Anti-Phospholipid Syndrome Score | Q44993606 | ||
| Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant | Q45013061 | ||
| beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome | Q45021710 | ||
| Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells | Q45033718 | ||
| Assessing the variation in antiphospholipid antibody (APA) assays: comparison of results from 10 centers | Q45041423 | ||
| Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation | Q45111033 | ||
| IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis | Q45126748 | ||
| The global anti-phospholipid syndrome score in primary APS. | Q45130401 | ||
| Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin | Q45220126 | ||
| Update on the catastrophic antiphospholipid syndrome and the "CAPS Registry". | Q45780878 | ||
| The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in individuals receiving or not receiving an oral vitamin K antagonist. | Q45967639 | ||
| Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial | Q46125985 | ||
| Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. | Q46252581 | ||
| Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. | Q46651769 | ||
| Warfarin and the antiphospholipid syndrome: does one size fit all? | Q46873547 | ||
| In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies | Q46982839 | ||
| Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. | Q47743642 | ||
| Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin | Q47868175 | ||
| Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome | Q49042052 | ||
| Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome | Q50172456 | ||
| Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. | Q50196335 | ||
| Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. | Q50619255 | ||
| Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. | Q53082840 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. | Q53354829 | ||
| Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome. | Q53533989 | ||
| A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. | Q53598537 | ||
| Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. | Q53874974 | ||
| Annexin A2 mediates endothelial cell activation by antiphospholipid/anti- 2 glycoprotein I antibodies | Q57374964 | ||
| Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome | Q57624160 | ||
| Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients | Q57907773 | ||
| Induction of anti-β2-glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes | Q57983447 | ||
| Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal Transplantation | Q58048140 | ||
| Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: Domain I of β2-glycoprotein I harbors a cryptic immunogenic epitope | Q58895662 | ||
| Anti–β2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts | Q59140753 | ||
| Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug | Q33747286 | ||
| β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. | Q33796355 | ||
| Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. | Q33967600 | ||
| Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression | Q34003992 | ||
| The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway | Q34021223 | ||
| On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies | Q34195707 | ||
| beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation | Q34245642 | ||
| The pathogenesis of the antiphospholipid syndrome | Q34332601 | ||
| A role for Toll-like receptor mediated signals in neutrophils in the pathogenesis of the anti-phospholipid syndrome | Q34364580 | ||
| 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends | Q34400373 | ||
| Monitoring warfarin therapy in patients with lupus anticoagulants | Q34434408 | ||
| Viral infections and antiphospholipid antibodies | Q34522953 | ||
| Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. | Q34566135 | ||
| Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study | Q34619943 | ||
| A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. | Q35124036 | ||
| CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis | Q35746486 | ||
| Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay | Q35792021 | ||
| Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome | Q35849691 | ||
| Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome | Q35874202 | ||
| Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. | Q35895238 | ||
| Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome | Q35953541 | ||
| Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury | Q36007691 | ||
| Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies | Q36013878 | ||
| Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity | Q36157442 | ||
| Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) | Q36242479 | ||
| RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. | Q36403678 | ||
| Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers | Q36843689 | ||
| Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome | Q36890849 | ||
| A novel pathway of cellular activation mediated by antiphospholipid antibody-induced extracellular vesicles | Q36928587 | ||
| The antiphospholipid syndrome: still an enigma | Q36928593 | ||
| Role of nucleic acid-sensing TLRs in diverse autoantibody specificities and anti-nuclear antibody-producing B cells | Q37059648 | ||
| Rivaroxaban - a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases | Q37141430 | ||
| Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial | Q37230504 | ||
| Pediatric antiphospholipid antibodies and antiphospholipid syndrome | Q37249533 | ||
| Anti-β2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway | Q37349421 | ||
| Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system | Q37378113 | ||
| Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome | Q37473270 | ||
| A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients | Q37702168 | ||
| The mosaic of "seronegative" antiphospholipid syndrome | Q37704857 | ||
| Isolated IgA anti- β2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome | Q37704874 | ||
| The dual role of innate immunity in the antiphospholipid syndrome | Q37721589 | ||
| Challenges in the diagnosis of the antiphospholipid syndrome | Q37723113 | ||
| Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis | Q37760751 | ||
| Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients | Q37803363 | ||
| Antiphospholipid antibodies--we are not quite there yet. | Q37829519 | ||
| Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS'). | Q37939702 | ||
| The contribution of antiphosphatidylethanolamine antibodies in the diagnosis of the antiphospholipid syndrome | Q38013586 | ||
| Seronegative antiphospholipid syndrome | Q38090375 | ||
| Novel anticoagulants and laboratory testing | Q38099419 | ||
| Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review | Q38113968 | ||
| Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab | Q38115382 | ||
| Standardization of antiphospholipid antibody testing--historical perspectives and ongoing initiatives | Q38182509 | ||
| Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication | Q38313174 | ||
| Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review | Q38392607 | ||
| Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. | Q38416654 | ||
| The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome. | Q38866404 | ||
| Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry | Q38957667 | ||
| Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study | Q39138695 | ||
| Anti-β(2)GPI/β(2)GPI induced TF and TNF-α expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways | Q39281957 | ||
| Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome | Q39608521 | ||
| Clinical course of high-risk patients diagnosed with antiphospholipid syndrome | Q39934417 | ||
| Direct oral anticoagulants in antiphospholipid syndrome: a real life case series | Q40131133 | ||
| The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. | Q40474976 | ||
| Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis | Q40639743 | ||
| CIRCULATING MICROPARTICLES, BLOOD CELLS, AND ENDOTHELIUM INDUCE PROCOAGULANT ACTIVITY IN SEPSIS THROUGH PHOSPHATIDYLSERINE EXPOSURE. | Q40932437 | ||
| Pregnancy Loss in the Antiphospholipid-Antibody Syndrome — A Possible Thrombogenic Mechanism | Q41099260 | ||
| Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). | Q41157732 | ||
| A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor | Q41211826 | ||
| Rivaroxaban and false positive lupus anticoagulant testing | Q60619095 | ||
| Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia | Q61415575 | ||
| Activation of complement mediates antiphospholipid antibody-induced pregnancy loss | Q61415576 | ||
| IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome | Q61649470 | ||
| Treatment of 139 Pregnancies in Antiphospholipid-positive Women Not Fulfilling Criteria for Antiphospholipid Syndrome: A Retrospective Study | Q61649488 | ||
| Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nîmes Obstetricians and Haematologists Study--NOHA | Q61853593 | ||
| Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti-β2-Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β2-Glycoprotein I and Induce Endothelial Activation | Q62395215 | ||
| Platelet adhesion to dimeric β2-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibαand apolipoprotein E receptor 2′ | Q63346659 | ||
| Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. | Q64897464 | ||
| Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin | Q67866864 | ||
| Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells | Q67939870 | ||
| Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant | Q69241643 | ||
| Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis | Q70529807 | ||
| Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH | Q70897451 | ||
| Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases | Q71654278 | ||
| Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion | Q72361563 | ||
| Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes | Q72384713 | ||
| Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone | Q73143663 | ||
| Systemic endothelial cell markers in primary antiphospholipid syndrome | Q73322507 | ||
| High levels of coagulation factor XI as a risk factor for venous thrombosis | Q73520981 | ||
| Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA | Q78321143 | ||
| Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids | Q78321169 | ||
| Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants | Q79339543 | ||
| Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome | Q79826484 | ||
| Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V | Q79992039 | ||
| Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome | Q80826802 | ||
| Lupus anticoagulants and the risk of a first episode of deep venous thrombosis | Q81064718 | ||
| Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C | Q81620372 | ||
| Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography | Q83162733 | ||
| Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies | Q83389363 | ||
| Antiphospholipid antibodies and the protein C pathway | Q83954291 | ||
| The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease | Q84143873 | ||
| Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study | Q84302565 | ||
| Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time | Q84349009 | ||
| Factor XI is a substrate for oxidoreductases: enhanced activation of reduced FXI and its role in antiphospholipid syndrome thrombosis | Q84390547 | ||
| The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study | Q84438431 | ||
| Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells | Q84513241 | ||
| Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events | Q85002100 | ||
| An international multicentre‐laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti‐beta2‐glycoprotein autoantibodies | Q85100865 | ||
| Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant | Q85743774 | ||
| An independent validation of the Global Anti-Phospholipid Syndrome Score in a Japanese cohort of patients with autoimmune diseases | Q86077231 | ||
| Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk | Q86646346 | ||
| The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases | Q86704919 | ||
| Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism | Q87211442 | ||
| New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome | Q87417887 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 406-417 | |
| P577 | publication date | 2017-07-30 | |
| P1433 | published in | Blood Reviews | Q15724415 |
| P1476 | title | Diagnosis and management of the antiphospholipid syndrome | |
| P478 | volume | 31 |
| Q90029392 | Anticoagulating patients with high-risk acquired thrombophilias |
| Q90428389 | FcRn augments induction of tissue factor activity by IgG-containing immune complexes |
| Q97652805 | Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants |
| Q91715407 | Pediatric antiphospholipid syndrome |
| Q64120268 | Role of TLR‑4 in anti‑β2‑glycoprotein I‑induced activation of peritoneal macrophages and vascular endothelial cells in mice |
| Q89638646 | Successful treatment with rivaroxaban for an acute pulmonary thromboembolism in a patient with primary antiphospholipid antibody syndrome |
Search more.